Abstract
There are approximately 500 species of predatory cone snails within the genus Conus. They comprise what is arguably the largest single genus of marine animals alive today. It has been estimated that the venom of each Conus species has between 50 and 200 components. These highly constrained sulfur rich components or conotoxins represent a unique arsenal of neuropharmacologically active peptides that have been evolutionarily tailored to afford unprecedented and exquisite selectivity for a wide variety of ion-channel subtypes. Remarkable divergence occurs when cone snails speciate. Consequently, the complement of venom peptides in any one Conus species is distinct from that of any other species. Hence many thousands of peptides that modulate ion channel function are present within Conus venoms. Evolutionary pressures have afforded a pre-optimized, structurally sophisticated library that has been fine tuned over 50 million years. The statistics associated with sampling such libraries bear testimony to the validity and feasibility of this strategy. Although approximately 100 conotoxin sequences have been published in the scientific literature, representing a mere 0.2 pecent of the estimated library size, this sample has already afforded a peptide of proven clinical utility and several pre-clinical leads for CNS disorders. Conus libraries represent a rich pharmacopoeia and the potential to therapeutically mine such a resource appears limitless. The paucity of synthetic methodologies necessary to achieve the regioisomeric folding patterns present in these native peptides precludes access to synthetic conotoxin libraries, further validating the overall mining strategy. In this article, we will present a pragmatic overview of the molecular diversity as well as the neurobiological mechanisms that define each major class of conotoxin.
Keywords: Conotoxins, Peptide Therapeutics, Conantokins, Contulakins, Conodipines, Phospholipid, nAChRs, Phyllomedusa, Agelenopsis aperta, Conus episcopatus, Conus radiatus, Contryphan and Bromocontryphan, Disulfide templates, ICK, Channel recognition motif, Potassium Channel Selective Conotoxins, Nicotinic Acetylcholine Channel (nAChR), Pisciorous Conus, Sodium channel selective conotoxins, Conus purpurascens, Ziconotide (SNX 111), Prostate cancer, Epilepsy, Anticonvulsants
Current Pharmaceutical Design
Title: Conotoxins-New Vistas for Peptide Therapeutics
Volume: 6 Issue: 12
Author(s): Robert M. Jones and Grzegorz Bulaj
Affiliation:
Keywords: Conotoxins, Peptide Therapeutics, Conantokins, Contulakins, Conodipines, Phospholipid, nAChRs, Phyllomedusa, Agelenopsis aperta, Conus episcopatus, Conus radiatus, Contryphan and Bromocontryphan, Disulfide templates, ICK, Channel recognition motif, Potassium Channel Selective Conotoxins, Nicotinic Acetylcholine Channel (nAChR), Pisciorous Conus, Sodium channel selective conotoxins, Conus purpurascens, Ziconotide (SNX 111), Prostate cancer, Epilepsy, Anticonvulsants
Abstract: There are approximately 500 species of predatory cone snails within the genus Conus. They comprise what is arguably the largest single genus of marine animals alive today. It has been estimated that the venom of each Conus species has between 50 and 200 components. These highly constrained sulfur rich components or conotoxins represent a unique arsenal of neuropharmacologically active peptides that have been evolutionarily tailored to afford unprecedented and exquisite selectivity for a wide variety of ion-channel subtypes. Remarkable divergence occurs when cone snails speciate. Consequently, the complement of venom peptides in any one Conus species is distinct from that of any other species. Hence many thousands of peptides that modulate ion channel function are present within Conus venoms. Evolutionary pressures have afforded a pre-optimized, structurally sophisticated library that has been fine tuned over 50 million years. The statistics associated with sampling such libraries bear testimony to the validity and feasibility of this strategy. Although approximately 100 conotoxin sequences have been published in the scientific literature, representing a mere 0.2 pecent of the estimated library size, this sample has already afforded a peptide of proven clinical utility and several pre-clinical leads for CNS disorders. Conus libraries represent a rich pharmacopoeia and the potential to therapeutically mine such a resource appears limitless. The paucity of synthetic methodologies necessary to achieve the regioisomeric folding patterns present in these native peptides precludes access to synthetic conotoxin libraries, further validating the overall mining strategy. In this article, we will present a pragmatic overview of the molecular diversity as well as the neurobiological mechanisms that define each major class of conotoxin.
Export Options
About this article
Cite this article as:
Jones M. Robert and Bulaj Grzegorz, Conotoxins-New Vistas for Peptide Therapeutics, Current Pharmaceutical Design 2000; 6 (12) . https://dx.doi.org/10.2174/1381612003399653
DOI https://dx.doi.org/10.2174/1381612003399653 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology Pharmacological Management of Huntingtons Disease: An Evidence- Based Review
Current Pharmaceutical Design Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Neuroactive Steroids as Endogenous Modulators of Anxiety
Current Pharmaceutical Design Antiepileptic Drugs in Clinical Development: Differentiate or Die?
Current Pharmaceutical Design Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence
CNS & Neurological Disorders - Drug Targets Diazenyl Derivatives as Therapeutic and Diagnostic Agents Acting on Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Routine Collection of Patient-Reported Outcomes in an HIV Clinic Setting:The First 100 Patients
Current HIV Research Epilepsy, Theories and Treatment Inside Corpus Hippocraticum
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Editorial [ Hot Topic: Recent Advances in Pediatric Epilepsy Surgery (Guest Editor: Batool F. Kirmani)]
Current Pediatric Reviews Nanoparticulate Drug Delivery in Pregnancy: Placental Passage and Fetal Exposure
Current Pharmaceutical Biotechnology Chvostek's Sign in Paediatric Practice
Current Pediatric Reviews Biological Evaluation of Imidazobenzoxazines, Imidazobenzoxazin-5-ones and Imidazobenzoxazin-5-thiones as Sodium Channel Blockers
Letters in Drug Design & Discovery Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets